Our characterisation of the Vhl/Trp53/Rb1 mutant mouse ccRCC model provides an experimental system that will allow the systematic dissection of the effects of individual and combined inhibition of these different checkpoint ligand/checkpoint receptor signalling systems on T cell activation in ccRCC. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.